PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT OF METHOTREXATE

被引：1
|
作者：
Song, Y. [1 ]
Xin, Y. [1 ]
Weinblatt, M. E. [2 ]
Chamberlain, J. [1 ]
Obermeyer, K. [3 ]
Zhao, L. [3 ]
Canavan, C. [3 ]
Peloso, P. M. [3 ]
Ramanathan, S. [1 ]
机构：
[1] Horizon Therapeut Plc, Res & Dev, San Francisco, CA USA
[2] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA
[3] Horizon Therapeut Plc, Res & Dev, Deerfield, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2136
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1136
引用
收藏
页码：847 / 848
页数：2
相关论文
共 50 条
  • [41] Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
    John K. Botson
    Katie Obermeyer
    Brian LaMoreaux
    Lin Zhao
    Michael E. Weinblatt
    Jeff Peterson
    Arthritis Research & Therapy, 24
  • [42] Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
    Bleyer, Anthony J.
    Wright, David E.
    Glicklich, Alan
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S497 - S498
  • [43] Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings
    Botson, John
    Obermeyer, Katie
    Lamoreaux, Brian
    Padnick-Silver, Lissa
    Verma, Supra
    Weinblatt, Michael E.
    Peterson, Jeff
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2024, 8 (04)
  • [44] Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis
    Bleyer, Anthony J.
    Wright, David
    Alcorn, Harry
    CLINICAL NEPHROLOGY, 2015, 83 (05) : 286 - 292
  • [45] Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
    Botson, John K. K.
    Obermeyer, Katie
    LaMoreaux, Brian
    Zhao, Lin
    Weinblatt, Michael E. E.
    Peterson, Jeff
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [46] Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
    John K. Botson
    Herbert S. B. Baraf
    Robert T. Keenan
    John Albert
    Karim R. Masri
    Jeff Peterson
    Christianne Yung
    Brigid Freyne
    Mona Amin
    Abdul Abdellatif
    Nehad Soloman
    N. Lawrence Edwards
    Vibeke Strand
    Current Rheumatology Reports, 2022, 24 : 12 - 19
  • [47] Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
    Botson, John K.
    Baraf, Herbert S. B.
    Keenan, Robert T.
    Albert, John
    Masri, Karim R.
    Peterson, Jeff
    Yung, Christianne
    Freyne, Brigid
    Amin, Mona
    Abdellatif, Abdul
    Soloman, Nehad
    Edwards, N. Lawrence
    Strand, Vibeke
    CURRENT RHEUMATOLOGY REPORTS, 2022, 24 (01) : 12 - 19
  • [48] Determinants of Red Blood Cell Methotrexate Polyglutamate Concentrations in Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Treatment
    Stamp, Lisa K.
    O'Donnell, John L.
    Chapman, Peter T.
    Zhang, Mei
    Frampton, Christopher
    James, Jill
    Barclay, Murray L.
    ARTHRITIS AND RHEUMATISM, 2009, 60 (08): : 2248 - 2256
  • [49] Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
    Choi, Hyon K.
    Johnson, Richard
    Yeo, Anthony
    Lipsky, Peter E.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [50] Methotrexate Polyglutamate Monitoring in Patients With Crohn's Disease
    Fischer, Monika
    Siva, Shivi
    Cook, Gwendolyn K.
    Jones, David R.
    Fadda, Hala M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (03): : 240 - 245
12345